<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800706</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-II-01</org_study_id>
    <nct_id>NCT03800706</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-Arm, Open-Label, Multicenter Clinical Trial. To observe the efficacy and safety of
      TQB2450 in patients of non-hodgkin lymphoma
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate(ORR)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Overall Response Rate (ORR) defined as the proportion of subjects who achieves a best response of CR or PR, assessed by IRC per the Lugano Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR)</measure>
    <time_frame>Up to 96 weeks</time_frame>
    <description>Disappearance of all non-target lesions and normalisation of tumour marker level. All lymph nodes must be non-pathological in size (&lt;10mm short axis).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Safety and Effectiveness</condition>
  <arm_group>
    <arm_group_label>TQB2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is injectived (IV) every-3-weeks (Q3W) and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent, the longest use time of experimental drugs is 96 weeks.</description>
    <arm_group_label>TQB2450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has voluntarily agreed to participate by giving written informed consent.;

          2. Histopathological confirmed classical Hodgkin's lymphoma;

          3. Relapsed/refractory cHL include：a)subject with relapse and progression after salvage
             chemotherapy followed by autologous stem cell transplantation(ASCT); b) subject with
             no ASCT: The first-line chemotherapy must be systemic multi-drug combination
             chemotherapy and subsequent chemotherapy requires at least one first-line chemotherapy
             must be systemic multi-drug combination chemotherapy; subject which is refractory
             didn't achieve PR after 2 cycles or didn't achieve CR after

          4. Age ranged from 18 to 75 years;

          5. At least one measurable disease ;

          6. Patients must have ECOG performance status of 0-2;

          7. Subject must have adequate organ functions ：Count of Blood Cells:hemoglobin
             content(HB)≥80g/L; absolute neutrophil count (ANC) ≥ 1.0 × 10^9 / L; platelet count
             (PLT) ≥ 75 × 10^9 / L;; Biochemical examination: serum total bilirubin (TBIL) ≤ 1.5 ×
             normal upper limit (ULN), with the exception of patients with hepatic metastases and
             Gilbert's syndrome(TBIL≤3×ULN） ; alanine aminotransferase (ALT) and aspartate
             aminotransferase (AST) ≤ 3 × ULN，with the exception of patients with hepatic
             metastases (ALT and AST ≤ 5 × ULN) , serum creatinine (Cr) ≤ 1.5 × ULN or Creatinine
             clearance rate（CCR）≥50 mL/min；Serum amylase and lipase ≤ 1.5 x ULN Blood coagulation
             function:International standardized ratio(INR)≤1.5×ULN、Activation partial thrombin
             time(APTT)≤1.5×ULN、Prothrombin time≤1.5×ULN；Doppler ultrasound evaluation：Left
             ventricular ejection fraction（LVEF)≥50%×MLN;

        Exclusion Criteria:

          -  1、Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma； 2、 Prior
             exposure to any anti-PD-1, anti-PD-L1 ， anti-CTLA-4 antibody or CAR-T cell
             treatment(Any other antibody that has been applied to a T cell synergistic stimulus or
             checkpoint pathway); 3、Need to therapy with other anticancer during the study;
             4、Received allogeneic organ transplantation or allogeneic hematopoietic stem cell
             transplantation;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuan Kai Shi</last_name>
    <phone>13701251865</phone>
    <email>syuankai@cicams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>No.17, panjiayuan nanli, chaoyang district, Beijing</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YuanKai Shi</last_name>
    </contact>
    <investigator>
      <last_name>YuanKai Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 9, 2019</study_first_submitted>
  <study_first_submitted_qc>January 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

